Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1726 studies found for:    HER2
Show Display Options
Rank Status Study
1 Unknown  HER2 Positive CTC in Advanced Gastric Cancer
Condition: HER2 Positive Advanced Gastric Cancer
Intervention: Device: Cell Search® CTC epithelial kit
2 Recruiting HER2-Peptide Vaccination of Patients With Solid Tumors
Conditions: Gastric Cancer;   Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Sargramostim;   Drug: HER2-Peptid-Vakzine;   Drug: Imiquimod
3 Active, not recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
4 Recruiting A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Conditions: Breast Cancer;   Ovarian Cancer;   Lung Cancer;   Gastric Cancer;   Colorectal Cancer;   Glioma;   Pancreatic Cancer
Intervention: Biological: Anti-HER2 CAR-T
5 Unknown  HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Condition: HER2-positive Breast Cancer
Intervention: Other: Radiolabeled [68Ga]ABY-025
6 Recruiting T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
Condition: Glioblastoma
Intervention: Genetic: HER2-specific T cells
7 Recruiting Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
Conditions: Advanced HER-2 Positive Solid Tumors;   Chemotherapy Refactory;   HER-2 Antibody Inhibitor Therapy Refactory
Intervention: Biological: CART-HER-2
8 Unknown  Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
Condition: Stomach Neoplasms
Intervention:
9 Recruiting Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Condition: HER2 Positive Breast Cancer
Interventions: Drug: ONT-380;   Drug: Capecitabine;   Drug: Trastuzumab;   Drug: Placebo
10 Recruiting Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
Conditions: Early-Stage Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: docetaxel + trastuzumab sc + pertuzumab;   Drug: trastuzumab emtansin
11 Recruiting Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Conditions: Breast Neoplasms;   Breast Cancer;   Adenocarcinomas;   Metastatic Solid Tumors Characterized by HER2/Neu Expression
Intervention: Biological: Autologous Ad HER2 dendritic cell vaccine
12 Unknown  Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
13 Enrolling by invitation Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Conditions: HER2/Neu Positive;   HLA-A2 Positive Cells Present;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer
Interventions: Biological: HER-2/neu Peptide Vaccine;   Other: Laboratory Biomarker Analysis
14 Recruiting Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
Condition: HER2-expressing Cancers
Intervention: Drug: ZW25, HER2 inhibitor
15 Recruiting Cardiac Safety Study in Patients With HER2 + Breast Cancer
Conditions: HER2 Positive Breast Cancer;   Left Ventricular Function Systolic Dysfunction
Intervention: Drug: Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine
16 Withdrawn HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
Condition: Breast Cancer With Brain Metastasis
Intervention: Radiation: Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
17 Completed Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Conditions: Breast Neoplasms;   Secondary;   HER2 Positive Carcinoma of Breast
Intervention: Drug: Zr89-trastuzumab
18 Recruiting Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
Conditions: Liver Metastasis;   Gastric Cancer
Interventions: Biological: PIK-HER2;   Biological: DC-PMAT
19 Recruiting Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Condition: Patients With Metastatic Breast Cancer Considered HER2 Negative on Primary Tumor.
Intervention: Drug: Trastuzumab - Emtansine
20 Recruiting Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
Condition: HER2 Expressing Solid Tumours
Intervention: Drug: CD3/HER2 bispecific monoclonal antibody

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.